Skip to main content
Premium Trial:

Request an Annual Quote

SurroMed and Fidelity Biosciences in Research Agreement

NEW YORK, Feb. 10 - Fidelity Biosciences Group, a division of Fidelity Investments, is providing SurroMed with an undisclosed amount of funding to discover and develop biomarkers and diagnostic products for neurodegenerative conditions, the companies said today.


Under the multi-year agreement, SurroMed will analyze preclinical and clinical samples using its proprietary protein analysis platform.


SurroMed will share in the commercialization of any resulting biomarkers. Further financial terms were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.